Zynerba Pharmaceuticals Inc (ZYNE.OQ)
ZYNE.OQ on NASDAQ Stock Exchange Global Market
10.56USD
20 Apr 2018
10.56USD
20 Apr 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$10.56
$10.56
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
84,918
84,918
52-wk High
$24.94
$24.94
52-wk Low
$5.42
$5.42
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -0.69 | December | 23 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 2 | 2 | 2 | 1 |
| (2) OUTPERFORM | 4 | 4 | 4 | 2 |
| (3) HOLD | 2 | 2 | 2 | 2 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.00 | 2.00 | 2.00 | 2.20 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 7 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-18 | 7 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-18 | 8 | 0.00 | 0.00 | 0.00 | 0.35 |
| Year Ending Dec-19 | 7 | 0.00 | 0.00 | 0.00 | 4.20 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 8 | -0.69 | -0.48 | -1.13 | -0.66 |
| Quarter Ending Sep-18 | 8 | -0.73 | -0.54 | -1.13 | -0.68 |
| Year Ending Dec-18 | 8 | -2.80 | -2.30 | -3.95 | -2.57 |
| Year Ending Dec-19 | 7 | -2.63 | -2.18 | -3.98 | -2.53 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-17 | 0.03 | 0.00 | 0.03 | 100.00 |
| Quarter Ending Jun-17 | 0.05 | 0.00 | 0.05 | 100.00 |
| Quarter Ending Mar-17 | 0.08 | 0.00 | 0.08 | 100.00 |
| Quarter Ending Dec-16 | 0.00 | 0.00 | 0.00 | 100.00 |
| Earnings (per share) | ||||
| Quarter Ending Dec-17 | -0.60 | -0.60 | 0.00 | -0.62 |
| Quarter Ending Sep-17 | -0.59 | -0.63 | 0.04 | -6.53 |
| Quarter Ending Jun-17 | -0.60 | -0.64 | 0.04 | -6.67 |
| Quarter Ending Mar-17 | -0.55 | -0.60 | 0.05 | -8.34 |
| Quarter Ending Dec-16 | -0.75 | -0.70 | 0.05 | -6.35 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 |
| Year Ending Dec-19 | 0.00 | 0.00 | 0.00 | 0.00 | 4.20 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | -0.69 | -0.69 | -0.69 | -0.69 | -0.66 |
| Quarter Ending Sep-18 | -0.73 | -0.73 | -0.73 | -0.76 | -0.68 |
| Year Ending Dec-18 | -2.80 | -2.80 | -2.80 | -2.69 | -2.57 |
| Year Ending Dec-19 | -2.63 | -2.63 | -2.63 | -2.43 | -2.53 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
Earnings vs. 
Estimates- BRIEF-Zynerba Pharmaceuticals Appoints John P. Butler To Board Of Directors
- BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)
- BRIEF-Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60
- BRIEF-Zynerba Pharma Plans To Conduct Single Pivotal Study Of ZYN002 In Fragile X Syndrome To Support NDA Filing
- BRIEF-Zynerba Pharmaceuticals Inc Plans To Initiate Phase 2 Development Of ZYN001 In Tourette Syndrome By Year End